Hepatocellular Carcinoma

A new model has projected a substantial rise in the burden of metabolic dysfunction-associated steatotic liver disease in the U.S. by 2050, which could be minimized by effective preventive and management strategies, researchers wrote.

The FDA has approved nivolumab and hyaluronidase-nvhy for subcutaneous injection in adults with solid tumors in which nivolumab is indicated, according to a press release.

Older age but not high comorbidity burden was significantly associated with overall survival among patients with hepatocellular carcinoma, even those with early-stage disease, according to study results.

Incidence of hepatocellular carcinoma was significantly higher among cirrhotic patients coinfected with hepatitis B and D viruses compared with those with HBV alone, with researchers suggesting HDV “plays a direct role” in HCC occurrence.

SAN DIEGO — Patients with decompensated alcohol-associated cirrhosis and ascites taking naltrexone had lower risk for all-cause mortality and liver disease complications, including acute kidney injury and spontaneous bacterial peritonitis.

SAN DIEGO — Liver stiffness measurements may help predict the risk for hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease, as well as identify those in need of surveillance, according to data.

Survival for people with hepatocellular carcinoma has improved over the last decade, according to study results.

Patients who tested positive for hepatitis D virus antibodies were at greater risk for developing hepatocellular carcinoma and other adverse liver-related outcomes, often at a young age, according to study results.

Immunotherapy treatment may make liver transplant viable for patients with later-stage hepatocellular carcinoma provided they adhere to a 3-month waiting period, according to study results.

Every October marks Liver Cancer Awareness Month in an effort to raise awareness and improve advocacy and treatment for patients living with the disease.